Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1

References

• Curry T E, Jr, Osteen K G. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003; 24: 428–465
   PubMed Web of Science ®Google Scholar
• Shalev E, Goldman S, Ben-Shlomo I. The balance between MMP-9 and MMP-2 and their tissue inhibitor (TIMP-1) in luteinized granulosa cells: comparison between women with PCOS and normal ovulatory women. Mol Hum Reprod 2001; 7: 325–331
   PubMed Web of Science ®Google Scholar
• Lahav-Baratz S, Kraiem Z, Shiloh H, Koifman M, Ishai D, Dirnfeld M. Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization. Fertil Steril 2003; 79: 567–571
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo I, Goldman S, Shalev E. Regulation of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of MMP, and progesterone secretion in luteinized granulosa cells from normally ovulating women with polycystic ovary disease. Fertil Steril 2003; 79(Suppl 1)694–701
   Google Scholar
• Oksjoki S, Rahkonen O, Haarala M, Vuorio E, Anttila L. Differences in connective tissue gene expression between normally functioning, polycystic and post-menopausal ovaries. Mol Hum Reprod 2004; 10: 7–14
   Google Scholar
• Walch K, Nagele F, Zeillinger R, Vytiska-Binstorfer E, Huber J C, Hefler L A. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. Fertil Steril 2005; 83: 1565–1567
   PubMed Web of Science ®Google Scholar
• Lewandowski K C, Komorowski J, O'Callaghan C J, Tan B K, Chen J, Prelevic G M, Ranveda H S. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1173–1177
   PubMed Web of Science ®Google Scholar
• Coppock H A, White A, Aplin J D, Westwood M. Matrix metalloprotease-3 and -9 proteolyze insulin-like growth factor binding protein-1. Biol Reprod 2004; 71: 438–443
   PubMedGoogle Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47
   PubMed Web of Science ®Google Scholar
• Huet C, Monget P, Pisselet C, Hennequet C, Locatelli A, Monniaux D. Chronology of events accompanying follicular atresia in hypophysectomized ewes. Changes in levels of steroidogenic enzymes, connexin 43, insulin-like growth factor II mannose 6 phosphate receptor, extracellular matrix components, and matrix metalloproteinases. Biol Reprod 1998; 58: 175–185
   PubMedGoogle Scholar
• Pitzel L, Ludemann S, Wuttke W. Secretion and gene expression of metalloproteinases and gene expression of their inhibitors in porcine corpora lutea at different stages of the luteal phase. Biol Reprod 2000; 62: 1121–1127
   Google Scholar
• Young K A, Hennebold J D, Stouffer R L. Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle. Mol Hum Reprod 2002; 8: 833–840
   PubMed Web of Science ®Google Scholar
• Duncan W C, Mcneilly A S, Illingworth P J. The effect of luteal ‘rescue’ on the expression and localization of matrix metalloproteinases and their tissue inhibitors in the human corpus luteum. J Clin Endocrinol Metab 1998; 83: 2470–2478
   PubMedGoogle Scholar
• Fowlkes J L, Enghild J J, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994; 269: 25742–25746
   PubMed Web of Science ®Google Scholar
• Mañes S, Mira E, Barbacid M M, Ciprés A, Fernández-Resa P, Buesa J M, Mérida I, Aracil M, Márquez G, Martínez-A C. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997; 272: 25706–25712
   PubMed Web of Science ®Google Scholar
• Fowlkes J L, Serra D M, Bunn R C, Thrailkill K M, Enghild J J, Nagase H. Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 2004; 145: 620–626
   PubMed Web of Science ®Google Scholar
• Duleba A J, Spaczynski R Z, Olive D L. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca interstitial cells. Fertil Steril 1998; 69: 335–340
   PubMed Web of Science ®Google Scholar
• Bergh C, Carlsson B, Olsson J H, Selleskog U, Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993; 59: 323–331
   PubMed Web of Science ®Google Scholar
• Erickson G F, Garzo V G, Magoffin D A. Insulin-like growth factor I (IGF-I) regulates aromatase activity in human granulosa and granulosa luteal cells. J Clin Endocrinol Metab 1989; 69: 716–724
   PubMed Web of Science ®Google Scholar
• Van Dessel H JHM, Lee P, Faessen G, Fauser B CJM, Giudice L C. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3030–3035
   Google Scholar